首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1516407

小分子無菌注射藥物市場 - 按藥物類型（抗生素、麻醉藥、抗病毒藥）、產品類型、給藥途徑、應用（腫瘤、傳染病、糖尿病）、配銷通路- 全球預測（2024 - 2032）

Small Molecule Sterile Injectable Drugs Market - By Drug Type (Antibiotics, Anaesthetics, Antivirals), Product Type, Route of Administration, Application (Oncology, Infectious Diseases, Diabetes), Distribution Channel - Global Forecast (2024 - 2032)

出版日期: 2024年04月11日 | 出版商:

Global Market Insights Inc. | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在大型製藥公司生產設施和能力大規模擴張的推動下，2024年至2032年全球小分子無菌注射藥物市場的複合年成長率將達到7.1%。這些公司正在大力投資以擴大其能力，以滿足全球對無菌注射劑不斷成長的需求。

例如，2024 年 2 月，美國私募股權公司 Selkirk Pharma, Inc. 收購了 1,000 股股票，並報告在其無菌生產設施中成功進行了無菌製程模擬 (APS)。該公司專注於小分子藥物的藥物輸送注射、填充和精加工，包括疫苗和合成化學品、生物製藥贊助商和醫藥產品。

這些化合物對許多醫療狀況很重要，包括傳染病、癌症和慢性病。擴展的製造流程使公司能夠提高供應鏈的效率、提高產品品質並更好地滿足監管標準。此外，技術和製造的進步使得新藥和療法的開發能夠推動市場成長。注射劑市場預計將進一步擴大，透過安全有效的注射劑解決方案滿足全球不斷成長的醫療保健需求。

小分子無菌注射藥物產業整體規模根據藥物類型、產品類型、給藥途徑、應用、配銷通路和地區進行分類。

2024年至2032年，來自抗生素領域的小分子無菌注射藥物收入將實現令人稱讚的複合年成長率。嚴重感染。

儘管全球抗生素傳染病的抗藥性不斷增強，但醫療保健提供者越來越依賴非處方抗生素注射劑來對抗細菌抗藥性並預防併發症。本公司不斷創新藥物消毒和製造技術，以滿足要求和監管標準。儘管醫療保健系統繼續優先考慮感染預防和病人安全，但對非處方注射抗生素的需求對於傳染病管理仍然很重要。

從2024 年到2032 年，學名藥細分市場將顯著成長。作用。這些藥物在感染、緩解疼痛和慢性病等各種疾病中都至關重要，確保患者和醫療保健提供者獲得負擔得起的治療。在嚴格的品質標準監管批准的推動下，學名藥無菌注射劑市場正在擴大，確保學名藥無菌注射劑保持與其註冊同類產品相當的性能和安全標準。

歐洲小分子無菌注射藥物市場從2024年到2032年將呈現顯著的複合年成長率。這些藥物對於治療多種疾病非常重要，包括感染、癌症和免疫系統疾病，透過注射提供有效且快速的緩解。

歐洲市場監管嚴格，注重品質標準，確保藥品供應安全可靠。隨著製藥公司擴大生產能力並推出新產品，歐洲對無藥注射劑的需求持續成長。這種成長推動了患者對醫療保健服務的需求，以改善結果和最佳化治療方案，使非侵入性注射劑成為縣級現代注射醫療保健實踐的基石。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病盛行率上升
  - 對個人化和標靶治療的需求不斷成長
  - 不斷成長的研發投資加速了活動
  - 藥物傳輸技術的進步
- 產業陷阱與挑戰
  - 開發和製造成本高
  - 嚴格的監管要求
成長潛力分析
管道分析
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

主要趨勢
抗生素
化療藥物
骨骼肌鬆弛劑
麻醉劑
抗凝血劑
抗驚厥藥
抗病毒藥
其他藥物類型

第 6 章：市場估計與預測：按產品類型，2021 - 2032 年

主要趨勢
品牌化
泛型

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
靜脈注射 (IV)
肌肉注射 (IM)
皮下注射（SC）

第 8 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
腫瘤學
傳染性疾病
糖尿病
肌肉骨骼
自體免疫疾病
心血管疾病
中樞神經系統疾病
其他應用

第 9 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 中東和非洲其他地區

第 11 章：公司簡介

AbbVie Inc.
Amgen Inc.
AstraZeneca Plc.
BioCryst Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Eli Lilly and Company
Fresenius Kabi USA
Gilead Sciences, Inc.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.

簡介目錄

Product Code: 9001

Global Small Molecule Sterile Injectable Drugs Market will observe a CAGR of 7.1% from 2024 to 2032, driven by the massive expansion of manufacturing facilities and capabilities of large pharmaceutical companies. These companies are investing heavily to expand their capabilities to meet the growing global demand for sterile injectables.

For instance, in February 2024, Selkirk Pharma, Inc., a United States-based private equity firm, acquired 1,000 shares and reported a successful Aseptic Process Simulation (APS) at its sterile manufacturing facility. The company specializes in pharmaceutical delivery injection, filling, and finishing of small molecules of drugs, including vaccines and synthetic chemicals, biopharmaceutical sponsors, and pharmaceutical products.

These compounds are important for many medical conditions, including infectious diseases, cancer, and chronic diseases. Extended manufacturing processes enable companies to improve the efficiency of their supply chains, improve product quality, and better meet regulatory standards. Furthermore, advances in technology and manufacturing enable the development of new drugs and therapies to drive market growth. The injectables market is poised for further expansion, meeting the growing healthcare needs across the globe with safe and effective injectable solutions.

Overall small molecule sterile injectable drugs industry size is classified based on drug type, product type, route of administration, application, distribution channel, and region.

The small molecule sterile injectable drugs revenue from the antibiotics segment will register a commendable CAGR from 2024 to 2032. Injectable antibiotics ensure rapid delivery and high bioavailability, making them useful in severe infections where oral therapy may be ineffective.

While antibiotic infectious disease resistance is increasing globally, healthcare providers rely increasingly on over-the-counter antibiotic injections to combat bacterial resistance and prevent complications. Companies continue to innovate in drug disinfection and manufacturing technology to meet requirements and regulatory standards. While the healthcare system continues to prioritize infection prevention and patient safety, the demand for over-the-counter injectable antibiotics remains important for infectious disease management.

The generic segment will witness an appreciable growth from 2024 to 2032. Generic sterile injectables offer cost-effective therapeutic options compared to brand counterparts, making them important in healthcare systems worldwide. These drugs are critical in various conditions such as infection, pain relief, and chronic diseases, ensuring access to affordable treatments for patients and healthcare providers. The generic sterile injectable market is expanding, driven by strict regulatory approvals for its standards of quality, ensuring that generic sterile injectables maintain performance and safety standards comparable to their registered counterparts.

Europe Small molecule sterile injectable drugs market will exhibit a notable CAGR from 2024 to 2032. An aging population, increasing rates of chronic diseases, and improvements in health care in the region support market growth. These drugs are important for the treatment of a wide range of conditions, including infection, cancer, and immune system diseases, providing effective and rapid relief through injections.

European market regulates strict compliance and emphasizes on quality standards, ensuring a safe and reliable supply of medicines. As pharmaceutical companies expand their manufacturing capacity and introduce new products, the demand for drug-free injectables continues to rise in Europe. This growth underlies the demand for healthcare services for patients to improve outcomes and optimize treatment options, making non-invasive injectables the cornerstone of modern injection healthcare practices at the county level.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of chronic diseases
  - 3.2.1.2 Rising demand for personalised and targeted therapies
  - 3.2.1.3 Growing R&D investment accelerated activities
  - 3.2.1.4 Advancement in drug delivery technology
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of development and manufacturing
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Antibiotics
5.3 Chemotherapy agents
5.4 Skeletal muscle relaxants
5.5 Anaesthetics
5.6 Anticoagulants
5.7 Anticonvulsants
5.8 Antivirals
5.9 Other drug types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Branded
6.3 Generics

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Intravenous (IV)
7.3 Intramuscular (IM)
7.4 Subcutaneous (SC)

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oncology
8.3 Infectious diseases
8.4 Diabetes
8.5 Musculoskeletal
8.6 Autoimmune disorders
8.7 Cardiovascular diseases
8.8 CNS disorders
8.9 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 Saudi Arabia
- 10.6.2 South Africa
- 10.6.3 Rest of Middle East and Africa